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e39–110.Atrial Dysfunction Assessed by Cardiac
Magnetic Resonance as an Early Marker of
Fabry CardiomyopathyAnderson-Fabry disease (AFD) cardiomyopathy is
characterized by glycosphingolipid (Gb3) storage
in all cellular components, with consequent
left ventricular hypertrophy (LVH). Gb3 accumula-
tion also involves atrial myocytes (1), ultimately
leading to left atrial (LA) enlargement and
reduced atrial compliance. Cardiac magnetic
resonance (CMR) plays an important role in the
assessment of the severity of Fabry
cardiomyopathy. CMR feature tracking (CMR-FT)
specifically allows the assessment of myocardial
strain from cine images (2).
Previous studies investigated LA strain in AFD by
speckle-tracking echocardiography but did not
explore the relationship between LA dysfunction and
severity of LV involvement (3). We aimed to evaluate
whether LA impairment may precede LV remodeling,
representing an expression of atrial myopathy related
to Gb3 accumulation.
In this retrospective, observational study, 45 pa-
tients with AFD underwent CMR with T1 mapping
using shortened modified Look-Locker inversion re-
covery sequences, 2-dimensional echocardiography,and quantification of Mainz Severity Score Index
(MSSI). Patients were divided into 3 groups (n ¼ 15
each) with increasing severity: 1) normal T1, no LVH;
2) low T1, no LVH; and 3) LVH. Patients were
compared with 15 healthy control subjects. CMR-FT
was applied for the analysis of LA strain (total,
conduit, booster) and volumes.
Mean age of the patients with AFD was 38.5  15.1
years; there were 34 (56%) men. No differences in sex
distribution and “classic” mutation prevalence were
found between groups. Higher values of global or
cardiovascular MSSI, rate of patients assuming
enzyme replacement therapy, indexed LV mass, LV
maximum wall thickness, and late gadolinium
enhancement–positive segments were observed from
groups 1 to 3, reflecting a gradient of disease severity.
Native T1 values were normal in healthy control
subjects and in group 1 patients and were progres-
sively lower in group 2 and 3.
LA total strain was comparable between control
subjects and patients in group 1 (36.8  6.4% vs.
36.8  6.0%; p ¼ 0.45), while a significant difference
was found between group 1 and group 2 (36.8  6.4%
vs. 29.9  5.2%; p ¼ 0.01). Group 3 showed a signifi-
cantly reduced LA total strain compared with all other
groups (19.6  4.8%; p < 0.001 for all). A progressive
reduction in LA conduit strain was observed from
control subjects to group 3, paralleling the increase in
patients with echocardiographic diastolic dysfunc-
tion. No difference among groups was found in LA
booster strain values (Figure 1). Atrial volumes were
significantly increased in group 3 compared with the
other groups. Overall, LA total strain showed very
good correlation with native septal T1, LV maximum
wall thickness, atrial volumes, and global or
cardiovascular MSSI. Univariate regression analysis
showed a significant association between LA total
strain and age, native septal T1, and MSSI but not
with sex or presence of “classic” mutations.
This is the first study systematically assessing LA
function by CMR-FT in a population of patients with
AFD stratified according to the degree of LV
involvement. Atrial deformation was already
impaired in patients with AFD with low T1 values
(tracking Gb3 deposition), even in the absence of LVH
and diastolic dysfunction. This is consistent with the
concept of an atrial myopathy directly caused by Gb3
deposition, primarily affecting atrial compliance.
Glycosphingolipid storage in the atrial myocardium
has been previously reported in histological studies,
regardless of LVH or enzyme replacement therapy
(1,4). As observed in hypertrophic cardiomyopathy,
atrial myopathy in AFD seems to affect primarily LA



































Moving from control subjects to group 3, a progressive reduction in left atrial (LA) total strain (εs) and conduit strain (εe) with lowering of T1 values and increase of left
ventricular mass can be observed. LA booster strain (εa) is preserved also in the last stages of cardiomyopathy. LGE ¼ late gadolinium enhancement.
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2263compliance rather than atrial contractility. The atrial
myopathy appears to progress in parallel with the
ventricular features of AFD cardiomyopathy as well
as its extracardiac manifestations, regardless of
male sex or presence of a classic mutation. In
particular, a good correlation was found with nativeT1 values, which in pre-hypertrophic patients with
AFD had been shown to provide prognostic
information (5).
In conclusion, this study contributes to the charac-
terization of the pre-hypertrophic phenotype of AFD,
introducing LA total strain as a potential novel
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2264indicator of early cardiac involvement and a possible
tool to personalize management decisions in these
patients.
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e008424.Ischemic Myocardial Burden Subtended by
Computed Tomography–Derived
Fractional Flow Reserve
(APPROACHFFRCT)An Exploratory Analysis on Diagnostic PerformanceFractional flow reserve derived from coronary
computed tomography angiography (FFRCT) is an
emerging noninvasive modality that accurately
identifies ischemic vessels (1), although recent
evidence suggests that gray-zone FFRCT values
between 0.70 to 0.80 are associated with only
modest diagnostic accuracy. The ischemic
myocardial burden is an established metric used to
guide clinical decision making and is traditionally
assessed using noninvasive stress imaging. The
potential to incorporate FFRCT values (“depth” of
ischemia), together with CT-derived ischemic
myocardial burden (“extent” of ischemia), has yet to
be explored and may improve the diagnosis of
hemodynamically significant coronary stenosis.
Therefore, the aim of this study was to evaluate the
incremental diagnostic performance of FFRCT-
defined ischemic myocardial burden when
compared with FFRCT alone in FFRCT significant
vessels (#0.80).
This is a subanalysis of the NXT (Analysis of Cor-
onary Blood Flow Using CT Angiography: Next Steps)
trial, a prospective study of stable coronary artery
disease patients undergoing CT angiography, FFRCT,
and FFR (1). We included 109 patients and 181 vessels
with FFRCT #0.80 (mean age 63.0  9.7 years; 75%
men). Burden of ischemic myocardium was defined
as percentage of left ventricular myocardium
subtended beyond the point at which the vessel
FFRCT becomes #0.80, as estimated by the
APPROACH (APPROACHFFRCT) score (Figures 1A to
1C). The APPROACH (Alberta Provincial Project for
Outcome Assessment in Coronary Heart Disease)
score is a cardiac magnetic resonance–validated
scoring matrix providing an anatomic estimate of
the myocardial territory at risk based on vessel
